Antifungal Activity of Efinaconazole Compared with Fluconazole, Itraconazole, and Terbinafine Against Terbinafine- and Itraconazole-Resistant/Susceptible Clinical Isolates of Dermatophytes, Candida, and Molds

被引:4
作者
Gamal, Ahmed [1 ]
Elshaer, Mohammed [1 ,2 ]
Long, Lisa [1 ]
Mccormick, Thomas S. [1 ]
Elewski, Boni [3 ]
Ghannoum, Mahmoud A. [1 ,4 ]
机构
[1] Case Western Reserve Univ, Ctr Med Mycol & Integrated Microbiome Core, Dept Dermatol, Cleveland, OH USA
[2] Mansoura Univ, Fac Med, Clin Pathol Dept, Mansoura, Egypt
[3] Univ Birmingham, Dept Dermatol, Birmingham, AL USA
[4] Univ Hosp Cleveland Med Ctr, Cleveland, OH USA
关键词
SUPERFICIAL DERMATOPHYTOSIS; FUNGAL-INFECTIONS; CANDIDA-AURIS; RESISTANCE; VORICONAZOLE; MECHANISM; ALBICANS; TRIAZOLE;
D O I
10.7547/22-132
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background: Recently, an increasing number of resistant-to-terbinafine dermatophytosis cases have been reported. Thus, identifying an alternative antifungal agent that possesses broad-spectrum activity, including against resistant strains, is needed. Methods: We compared the antifungal activity of efinaconazole with that of fluconazole, itraconazole, and terbinafine against clinical isolates of dermatophytes, Candida, and molds using in vitro assays. Minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) of each antifungal agent were quantified and compared. Susceptible and resistant clinical isolates of Trichophyton mentagrophytes (n = 16), Trichophyton rubrum (n = 43), Trichophyton tonsurans (n = 18), Trichophyton violaceum (n = 4), Candida albicans (n = 55), Candida auris (n = 30), Fusarium spp, Scedosporium spp, and Scopulariopsis spp (n = 15 for each) were tested. Results: Efinaconazole was the most active antifungal agent tested against dermatophytes, with MIC50 and MIC90 (concentrations that inhibited 50% and 90% of strains tested, respectively) values of 0.002 and 0.03 mu g/mL, respectively. Fluconazole, itraconazole, and terbinafine showed MIC50 and MIC90 values of 1 and 8 mu g/mL, 0.03 and 0.25 mu g/mL, and 0.03 and 16 mu g/mL, respectively. Against Candida isolates, efinaconazole MIC50 and MIC90 values were 0.016 and 0.25 mu g/mL, respectively, whereas fluconazole, itraconazole, and terbinafine had MIC50 and MIC90 values of 1 and 16 mu g/mL, 0.25 and 0.5 mu g/mL, and 2 and 8 mu g/mL, respectively. Against various mold species, efinaconazole MIC values ranged from 0.016 to 2 mu g/mL versus 0.5 to greater than 64 mu g/mL for the comparators. Conclusions: Efinaconazole showed superior potent activity against a broad panel of susceptible and resistant dermatophyte, Candida, and mold isolates. (J Am Podiatr Med Assoc
引用
收藏
页数:8
相关论文
共 55 条
[1]   Candida auris: From Multidrug Resistance to Pan-Resistant Strains [J].
Ademe, Muluneh ;
Girma, Friehiwot .
INFECTION AND DRUG RESISTANCE, 2020, 13 :1287-1294
[2]  
Aly R., 1996, Medical Microbiology, V4th
[3]  
[Anonymous], 2008, Reference method for broth dilution antifungal susceptibility testing of yeasts
[4]  
[Anonymous], Food and Drug Administration (FDA). 2018. Available at: https://www.fda.gov/downloads/Food/IngredientsPackagingLabeling/GEPlants/Submissions/ucm592625.pdf (accessed 1 March 2018).
[5]   Point mutations in the squalene epoxidase gene of Indian ITS genotype VIII T. mentagrophytes identified after DNA isolation from infected scales [J].
Burmester, Anke ;
Hipler, Uta-Christina ;
Hensche, Reka ;
Elsner, Peter ;
Wiegand, Cornelia .
MEDICAL MYCOLOGY CASE REPORTS, 2019, 26 :23-24
[6]  
CLSI, 2017, CLSI standard M38, Vthird
[7]   Mechanisms of Antifungal Drug Resistance [J].
Cowen, Leah E. ;
Sanglard, Dominique ;
Howard, Susan J. ;
Rogers, P. David ;
Perlin, David S. .
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2015, 5 (07)
[8]   How to select an antifungal agent in critically ill patients [J].
Dimopoulos, George ;
Antonopoulou, Anastasia ;
Armaganidis, Apostolos ;
Vincent, Jean-Louis .
JOURNAL OF CRITICAL CARE, 2013, 28 (05) :717-727
[9]   Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now [J].
Freire-Moran, Laura ;
Aronsson, Bo ;
Manz, Chris ;
Gyssens, Inge C. ;
So, Anthony D. ;
Monnet, Dominique L. ;
Cars, Otto .
DRUG RESISTANCE UPDATES, 2011, 14 (02) :118-124
[10]  
Gu David, 2020, JAAD Case Rep, V6, P1153, DOI 10.1016/j.jdcr.2020.05.025